2634-P: Effect of Weight Loss on Reversal of MASLD by Studying Noninvasive Fibrosis Scores in Indian Patients

Introduction and Objective: MASLD affects up to 40% of Indian adults with obesity and is leading cause of cirrhosis in India. Data on weight loss-induced reversal remain scarce in Indian populations, where genetic predisposition & metabolic phenotypes differ from Western cohorts. This study aims to evaluate the effect of weight loss on reversal of MASLD and across interventions of weight loss. Methods: A prospective observational cohort study included 200 participants with MASLD in a tertiary care hospital, India. Baseline assessment including anthropometric(wt, ht, waist, hip circ), HbA1c, LFT, elastography (CAP, LSM), non-invasive fibrosis scores (FIB-4, APRI, NFS) were assessed at baseline and at 12-24 weeks. Statistical analysis used repeated measures ANOVA (p<0.05 significant) Results: In 200 patients(mean age 45.2±11.8 yr, 55% female, 56% type 2 diabetes,41% hypertension). Baseline mean BMI 36.9±7.3 kg/m², weight 100.3±25.5 kg. Conclusion: Weight loss demonstrates dose-dependent MASLD reversal, even modest weight reduction yielding measurable hepatic improvement, greater weight loss proportionately enhances steatosis, fibrosis regression in Indian patients compared to western data. Bariatric surgery's superior efficacy in achieving greater weight loss translates to 2.6-3.3 x hepatic improvements compared to lifestyle modification, thus critical for optimizing MASLD management in India's high-burden metabolic disease landscape. Disclosure S. Ghosh: None. M. Jain: None. V. Bindal: None. M. Anand: None. S. Goel: None. A. Jain: None. I. Yaduvanshi: None.